Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 1 to 15 of 86 results for infliximab

  1. Infliximab for acute exacerbations of ulcerative colitis (TA163)

    Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    17 December 2008
    View recommendations

    Sections for TA163

  2. Infliximab for the treatment of adults with psoriasis (TA134)

    Evidence-based recommendations on infliximab for treating severe psoriasis in adults.

    Technology appraisal guidance
    Published
    23 January 2008
    View recommendations

    Sections for TA134

  3. Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

    Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.

    Technology appraisal guidance
    Published
    19 May 2010
    View recommendations

    Sections for TA187

  4. Spesolimab for treating generalised pustular psoriasis flares [ID3963]

    In development [GID-TA10871] Expected publication date: 18 June 2025

    Technology appraisal guidance
    In development

  5. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA199

  6. Pulmonary sarcoidosis: infliximab (ES2)

    Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

    Evidence summary
    Published
    20 December 2016

  7. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

    Evidence summary
    Published
    17 January 2017

  8. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA329

  9. Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715)

    Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked.

    Technology appraisal guidance
    Published
    14 July 2021
    View recommendations

    Sections for TA715

  10. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA195

  11. Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis

    Evidence summary
    Published
    21 July 2020

  12. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

    Evidence summary
    Published
    24 February 2021

  13. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.

    Technology appraisal guidance
    Published
    26 January 2016
    View recommendations

    Sections for TA375

  14. Crohn's disease: management (NG129)

    This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.

    NICE guideline
    Published
    3 May 2019
    View recommendations

    Sections for NG129

  15. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    20 June 2017